



November 7, 2025

**The General Manager**

Pakistan Stock Exchange Limited  
Stock Exchange Building,  
Stock Exchange Road,  
Karachi

**Subject: Material Information**

**Dear Sir,**

In compliance with Section 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Rule Book of Pakistan Stock Exchange Limited, we are pleased to inform that Macter International Limited ("the Company") has successfully launched Semaglutide in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) presentations.

Semaglutide is a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, a class of drugs widely used in the management of Type 2 Diabetes Mellitus and increasingly recognized for its role in weight management and metabolic health.

With this launch, Macter has become the only company in Pakistan offering Semaglutide in all three biotechnology dosage formats — Vials, Pre-Filled Syringes, and Pre-Filled Pens.

This milestone marks a significant advancement in Macter's Biotech portfolio and reinforces its leadership in bringing advanced, globally competitive therapies to patients in Pakistan.

Yours truly,  
For and on behalf of  
Macter International Limited

Asif Javed  
Company Secretary

CC: Director/HOD  
Supervision Division  
Securities & Exchange Commission of Pakistan  
NIC Building, 63 Jinnah Avenue, Blue Area,  
Islamabad